Using the National Cancer Data Base, patients with pretreatment clinical stage I/II pancreatic adenocarcinoma were identified. Treatment utilization and outcomes were assessed at VA compared with academic and community hospitals.
Of 35,009 patients, 2%were seen at VA, 38%at academic, and 54%at community hospitals. VA hospitals were more likely to use surgery (odds ratio 2.20, 95%confidence interval 1.73–2.79) and to administer adjuvant chemotherapy (odds ratio 1.77, confidence interval 1.28–2.46) compared with community hospitals. Adjusted perioperative mortality and 3-year survival rates after surgery were similar at VA and academic hospitals.
For localized pancreatic cancer, patients treated at VA hospitals receive stage-specific treatments and have risk-adjusted perioperative and long-term survival rates that are comparable with those for patients treated at academic centers.